Local drug delivery strategies for cancer treatment: Gels, nanoparticles, polymeric films, rods, and wafers

Wolinsky, Jesse B.; Colson, Yolonda L.; Grinstaff, Mark W.

doi:10.1016/j.jconrel.2011.11.031

Cited by 724 publications

(531 citation statements)

References 100 publications

Supporting

Mentioning

506

Contrasting

Unclassified

Order By: Relevance

“…Also, IP delivery increases the concentration of drug in the vicinity of hypoxic, small peritoneal metastases (less than 1 mm in diameter), which lack an established vasculature and are therefore difficult to treat using IV administration [16]. Finally, similar to any other regional cancer therapy, administration of drugs directly into the site of action lowers systemic toxic effects [17]. It should be noted that none of the available chemotherapeutics has been specifically approved for IP administration.…”

Section: Rationale Behind Using Ip Therapymentioning

confidence: 99%

Nanomedicine-based intraperitoneal therapy for the treatment of peritoneal carcinomatosis — Mission possible?

Dakwar

Shariati

Willaert

et al. 2017

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

Intraperitoneal (IP) drug delivery represents an attractive strategy for the local treatment of peritoneal carcinomatosis (PC). Over the past decade, a lot of effort has been put both in the academia and clinic in developing IP therapeutic approaches that maximize local efficacy while limiting systemic side effects. Also nanomedicines are under investigation for the treatment of tumors confined to the peritoneal cavity, due to their potential to increase the peritoneal retention and to target drugs to the tumor sites as compared to free drugs. Despite the progress reported by multiple clinical studies, there are no FDA approved drugs or formulations for specific use in the IP cavity yet. This review discusses the current clinical management of PC, as well as recent advances in nanomedicines-based IP delivery.We address important challenges to be overcome towards designing optimal nanocarriers for IP therapy in vivo.

show abstract

Section: Rationale Behind Using Ip Therapymentioning

confidence: 99%

Nanomedicine-based intraperitoneal therapy for the treatment of peritoneal carcinomatosis — Mission possible?

Dakwar

Shariati

Willaert

et al. 2017

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

show abstract

“…Based on depot systems that are implanted either directly into or adjacent to the tumor, the latter promotes the release of drug directly to the cancer site [31,32]. In recent years, numerous studies have been done with localized drug delivery strategies to treat cervical cancer.…”

Section: Systemic Versus Localized Drug Delivery Systemsmentioning

confidence: 99%

“…There are several benefits of localized drugs delivery to the cervix as compared with systemic delivery, such as prevention of systemic chemotherapeutic drug circulation resulting in less drug loss, decreased side effects, and delivery of a high dose of the active agent in the cervix, which in turn improves the efficacy of the treatment (Figure 5) [105]. The treatment of metastatic cervical tumors using localized drug carriers may be incompetent where the disease is spread in distant organs and demonstrates the necessity of a more systemic approach.…”

Section: Localized Drug Delivery Systemsmentioning

confidence: 99%

Possible role of nanocarriers in drug delivery against cervical cancer

Gupta

2017

Nano Reviews & Experiments

View full text Add to dashboard Cite

Introduction: Cervical cancer is the second most common cancer and the largest cancer killer among women in most developing countries including India. Although, various drugs have been developed for cervical cancer, treatment with these drugs often results in a number of undesirable side effects, toxicity and multidrug resistance (MDR). Also, the outcomes for cervical cancer patients remain poor after surgery and chemo radiation. Methods: A literature search (for drugs and delivery systems against cervical cancer) was performed on PubMed and through Google. The present review discuss about various methods including its current conventional treatment with special reference to recent advances in delivery systems encapsulating various anticancer drugs and natural plant products for targeting towards cervical cancer. The role of photothermal therapy, gene therapy and radiation therapy against cervical cancer is also discussed. Results: Systemic/targeted drug delivery systems including liposomes, nanoparticles, hydrogels, dendrimers etc. and localized drug delivery systems like cervical patches, films, rings etc. are safer than the conventional chemotherapy which has further been proved by the several drug delivery systems undergoing clinical trials. Conclusion: Novel approaches for the aggressive treatment of cervical cancer will optimistically result in decreased side effects as well as toxicity, frequency of administration of existing drugs, to overcome MDR and to increase the survival rates.

show abstract

“…Hydrogels are semi-solid forms of hydrophilic cross-linked polymers that have shown application in localised and slow release drug delivery systems [30,31], They act as delivery vehicles by trapping small drug molecules within the spaces between the polymer cross links.…”

Section: Introductionmentioning

confidence: 99%

A cisplatin slow-release hydrogel drug delivery system based on a formulation of the macrocycle cucurbit[7]uril, gelatin and polyvinyl alcohol

Oun¹,

Plumb²,

Wheate³

2014

Journal of Inorganic Biochemistry

View full text Add to dashboard Cite

The anticancer drug cisplatin was encapsulated within the cucurbit [7]uril macrocycle to form the host-guest complex: cisplatin@CB [7]. This was then incorporated into gelatin and 0-4% w/v polyvinyl alcohol (PVA)-based hydrogels as slow release drug delivery vehicles. The hydrogels demonstrated predicable swelling and disintegration dependent on the PVA concentration. The hydrogel with the highest PVA content was slower to swell and release drug compared with lower concentrations of PVA. The effect of the hydrogel PVA concentration on in vitro cytotoxicity was examined using A2780/CP70 ovarian cancer cells. Over the 24 h drug exposure time used, hydrogels containing 4% PVA showed a 20% decrease in viable cells compared to the control, whereas hydrogels containing 0% and 2% PVA induced an 80% and 45% inhibition of cell growth, respectively. There was no measurable difference in the in vitro cytotoxicity of free cisplatin and cisplatin@CB [7] containing hydrogels. Finally, the in vivo effectiveness of a 2%-PVA hydrogel implanted under the skin of nude mice bearing A2780/CP70 xenografts showed that low dose hydrogels containing cisplatin@CB [7] (30 µg equivalent of drug) was just as effective as an intraperitoneal high dose administration of free cisplatin (150 µg) at inhibiting tumour growth.

show abstract

Local drug delivery strategies for cancer treatment: Gels, nanoparticles, polymeric films, rods, and wafers

Cited by 724 publications

References 100 publications

Nanomedicine-based intraperitoneal therapy for the treatment of peritoneal carcinomatosis — Mission possible?

Nanomedicine-based intraperitoneal therapy for the treatment of peritoneal carcinomatosis — Mission possible?

Possible role of nanocarriers in drug delivery against cervical cancer

A cisplatin slow-release hydrogel drug delivery system based on a formulation of the macrocycle cucurbit[7]uril, gelatin and polyvinyl alcohol

Contact Info

Product

Resources

About